Caspase inhibitors for liver disease

Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data.

Infectious diseases and therapy·2023

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review.

Cardiology and therapy·2021

Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.

Journal of medical economics·2017

Stapled peptide induces cancer cell death.

Drug discovery today·2004

Actin strange.

Drug discovery today·2003

Drug type contributions to pharmaceutical innovation: A USA-China comparative analysis.

Drug discovery today·2026

Tumor hypoxia: Molecular pathways and therapeutic interventions.

Drug discovery today·2026

Degraders of histone lysine methyltransferases: Progress, challenges, and opportunities.

Drug discovery today·2026

Single-cell and spatial transcriptomic insights into fibrotic mechanisms and therapeutic opportunities.

Drug discovery today·2026

Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation.

Drug discovery today·2026

Precision targeting in prostate cancer: Mechanistic drivers and the evolving clinical pipeline.

Drug discovery today·2026

Lathyrol Targets G6PD to Disrupt Redox Homeostasis in Non-Small Cell Lung Cancer.

ACS omega·2026

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

JTO clinical and research reports·2026

Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice.

JTO clinical and research reports·2026

Use of the Behavioral Dyscontrol Scale-2 (BDS-2) to measure executive dysfunction in FXTAS.

Frontiers in molecular neuroscience·2026

Targeted niosomes protect the heart from doxorubicin-induced injury: evidence from oxidative stress, pyroptosis, and apoptosis pathways.

3 Biotech·2026

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Frontiers in oncology·2026

Related Experiment Videos

Caspase inhibitors for liver disease

Related Concept Videos

Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data.

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review.

Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.

Stapled peptide induces cancer cell death.

Actin strange.

Drug type contributions to pharmaceutical innovation: A USA-China comparative analysis.

Tumor hypoxia: Molecular pathways and therapeutic interventions.

Degraders of histone lysine methyltransferases: Progress, challenges, and opportunities.

Single-cell and spatial transcriptomic insights into fibrotic mechanisms and therapeutic opportunities.

Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation.

Precision targeting in prostate cancer: Mechanistic drivers and the evolving clinical pipeline.

Lathyrol Targets G6PD to Disrupt Redox Homeostasis in Non-Small Cell Lung Cancer.

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice.

Use of the Behavioral Dyscontrol Scale-2 (BDS-2) to measure executive dysfunction in FXTAS.

Targeted niosomes protect the heart from doxorubicin-induced injury: evidence from oxidative stress, pyroptosis, and apoptosis pathways.

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Related Experiment Videos

Caspase inhibitors for liver disease

Related Concept Videos

Related Articles